Therapy of IgA nephropathy.

Area of Science:

• Nephrology
• Immunology
• Internal Medicine

Background:

• Immunoglobulin A (IgA) nephropathy is the most prevalent form of glomerulonephritis globally, frequently leading to end-stage renal failure.
• Diagnosis relies on identifying dominant IgA mesangial deposits via immunofluorescence, distinguishing it from other conditions like minimal change disease with IgA deposits.
• Primary IgA nephropathy (Berger's disease) presents with macroscopic hematuria and persistent proteinuria, with approximately 25% of patients progressing to renal failure within a decade.

Purpose of the Study:

• To elucidate the pathogenesis of IgA nephropathy, focusing on mesangial deposition of IgA1-containing immune complexes and immune system dysregulation.
• To review current and emerging therapeutic strategies aimed at modulating the immune response and slowing disease progression.
• To identify prognostic markers and highlight areas for future research in managing IgA nephropathy.

Main Methods:

• Review of existing literature on IgA nephropathy pathogenesis, clinical manifestations, and treatment outcomes.
• Analysis of the role of B cell responses, T helper cell hyperactivity, and genetic factors in disease development.
• Evaluation of potential therapeutic interventions, including dietary changes, immune modulation, and pharmacological agents.

Main Results:

• Primary IgA nephropathy is associated with altered immune responses, potentially involving both mucosal and medullary IgA compartments.
• While some interventions like oligoantigenic diets show promise, practicality remains a challenge; pharmacological modulation of mucosal immunity appears more viable.
• Emerging evidence suggests immune interventions (azathioprine, IVIg) for proteinuric patients and combination therapies (ACE inhibitors, fish oil) may slow renal failure progression.

Conclusions:

• Understanding the complex immune mechanisms underlying IgA nephropathy is crucial for developing effective treatments.
• Targeting immune dysregulation and employing renoprotective strategies offer promising avenues for managing patients with IgA nephropathy.
• Further research is needed to validate the efficacy of early corticosteroid therapy and other unproven treatments, and the search for bacterial foci remains essential.